Success Metrics

Clinical Success Rate
100.0%

Based on 14 completed trials

Completion Rate
100%(14/14)
Active Trials
0(0%)
Results Posted
71%(10 trials)

Phase Distribution

Ph phase_2
10
59%
Ph phase_3
5
29%
Ph phase_1
2
12%

Phase Distribution

2

Early Stage

10

Mid Stage

5

Late Stage

Phase Distribution17 total trials
Phase 1Safety & dosage
2(11.8%)
Phase 2Efficacy & side effects
10(58.8%)
Phase 3Large-scale testing
5(29.4%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

14 of 14 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

17

all time

Status Distribution
Completed(14)
Other(3)

Detailed Status

Completed14
unknown3

Development Timeline

Analytics

Development Status

Total Trials
17
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (11.8%)
Phase 210 (58.8%)
Phase 35 (29.4%)

Trials by Status

unknown318%
completed1482%

Recent Activity

0 active trials
Showing 5 of 17
completedphase_2

Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Phototherapy in the Treatment of Nonsegmental Vitiligo (NSV)

NCT04525157
unknownphase_2

A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum C and V

NCT05370235
unknownphase_2

A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum (XP)

NCT05159752
completedphase_2

A Proof of Concept Study to Evaluate the Safety of Afamelanotide in Patients With Acute Arterial Ischaemic Stroke (AIS)

NCT04962503
unknownphase_2

A Study to Assess the Changes in Pigmentation and Safety of Afamelanotide in Patients With Vitiligo on the Face

NCT05210582
View all 17 trials

Clinical Trials (17)

Showing 17 of 17 trials
NCT04525157Phase 2

Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Phototherapy in the Treatment of Nonsegmental Vitiligo (NSV)

Completed
NCT05370235Phase 2

A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum C and V

Unknown
NCT05159752Phase 2

A Study to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Xeroderma Pigmentosum (XP)

Unknown
NCT04962503Phase 2

A Proof of Concept Study to Evaluate the Safety of Afamelanotide in Patients With Acute Arterial Ischaemic Stroke (AIS)

Completed
NCT05210582Phase 2

A Study to Assess the Changes in Pigmentation and Safety of Afamelanotide in Patients With Vitiligo on the Face

Unknown
NCT05368857Phase 1

DNA Repair Capacity of Afamelanotide on Ultraviolet Radiation-induced DNA Damage in Healthy Volunteers

Completed
NCT04943159Phase 2

Afamelanotide in Patients Suffering With Acne Vulgaris

Completed
NCT00979745Phase 3

Phase III Confirmatory Study in Erythropoietic Protoporphyria (EPP)

Completed
NCT04425746Phase 2

Afamelanotide as Adjunctive Therapy in Patients Undergoing Photodynamic Therapy (PDT) Utilising Porfimer Sodium

Completed
NCT04704713Phase 3

Afamelanotide in Patients Suffering From Polymorphic Light Eruption (PLE)

Completed
NCT04578496Phase 3

A Safety Extension Study in Patients With Erythropoietic Protoporphyria (EPP)

Completed
NCT01097044Phase 2

Phase II Confirmatory Study in Erythropoietic Protoporphyria (EPP)

Completed
NCT04053270Phase 3

Multicentre Phase III Erythropoietic Protoporphyria Study

Completed
NCT01605136Phase 3

Phase III Confirmatory Study in Erythropoietic Protoporphyria

Completed
NCT01382589Phase 2

Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo

Completed
NCT01430195Phase 1

Afamelanotide and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo (NSV)

Completed
NCT00859534Phase 2

Phase II Solar Urticaria (SU) Pilot Study

Completed

All 17 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
17